Thirty Percent Of Anticipated Net Price was Biofrontera’s largest revenue line in fiscal 2021, bringing in $100.00M of $200.00M (50%).
| Contract with Customer, Basis of Pricing | FY 2021 |
|---|---|
| Thirty Percent Of Anticipated Net Price | $100.00M |
| Forty Percent Of Anticipated Net Price | $100.00M |
| Total | $200.00M |
Biofrontera brought in $200.00M from its two revenue lines in fiscal 2021, the year ended October 8, 2021. Thirty Percent Of Anticipated Net Price was the largest at $100.00M (50.0%), ahead of Forty Percent Of Anticipated Net Price at $100.00M (50.0%).
Biofrontera (BFRI) reports its revenue by contract with customer, basis of pricing. In fiscal 2021, Thirty Percent Of Anticipated Net Price was its largest revenue line, bringing in $100.00M (50.0% of the total), followed by Forty Percent Of Anticipated Net Price at $100.00M (50.0%).
Thirty Percent Of Anticipated Net Price was Biofrontera's largest revenue line in fiscal 2021, bringing in $100.00M, or 50.0% of the $200.00M total across its two revenue lines.
Every figure comes from Biofrontera's annual financial filings, as reported. Each line keeps the name Biofrontera gives it, and years follow its fiscal calendar.
Biofrontera's revenue by contract with customer, basis of pricing goes back to fiscal 2021, with figures through fiscal 2021. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.